AbbVie (ABBV) Operating Expenses (2012 - 2026)

AbbVie has disclosed Operating Expenses across 15 years of filings, most recently posting $11.0 billion for Q1 2026.

• In Q1 2026, Operating Expenses rose 14.59% year-over-year to $11.0 billion; the TTM figure through Mar 2026 stood at $47.5 billion (changed 0.41% YoY), while the FY2025 annual figure was $46.1 billion, down 2.36% from the prior year.
• Operating Expenses slipped to $11.0 billion in Q1 2026, from $12.1 billion in the prior quarter.
• Over the last five years, Operating Expenses for ABBV reached as high as $16.6 billion in Q4 2024 and fell as low as $8.8 billion in Q1 2022.
• The 5-year median for Operating Expenses is $10.5 billion (2025), against an average of $10.9 billion.
• Annual changes were most pronounced in 2024 — Operating Expenses surged 49.4% — and 2025, when it fell 27.23%.
• A 5-year view of Operating Expenses shows it stood at $9.6 billion in 2022, then climbed by 15.46% to $11.1 billion in 2023, then surged by 49.4% to $16.6 billion in 2024, then retreated by 27.23% to $12.1 billion in 2025, then decreased by 8.8% to $11.0 billion in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $11.0 billion, $12.1 billion, and $13.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.